In this context, nmMLCK inhibition, with two inhibitors acting through two different mechanisms, prevents IL-6 secretion downstream of p65-NFκB activation, the increase of transendothelial migration and the endothelial dysfunction in aortas induced by IH. The gene discussed is IL6; the disease is endothelial dysfunction.